InvestorsHub Logo
Followers 78
Posts 11422
Boards Moderated 0
Alias Born 04/03/2014

Re: Whalatane post# 93

Tuesday, 11/26/2019 11:05:05 AM

Tuesday, November 26, 2019 11:05:05 AM

Post# of 1469
Agree - it is Monotherapy and if approved will automatically become Standard of Care.
The co does not have marketing capability so it will become takeover target easily


Also this is good news today on - 2 undisclosed indications

to advance two of Ardelyx's ongoing research programs focused on the identification and design of compounds to two undisclosed targets.

https://finance.yahoo.com/news/ardelyx-kyowa-kirin-expand-partnership-230000274.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ARDX News